title: Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma.
abstract: BACKGROUND
  To investigate on the expressions and the clinical significances of hepatocyte growth factor receptor (c-MET), phosphorylated c-MET (p-MET) and e2f-1 transcription factor in primary lesion of gastric adenocarcinoma (GC).
  
  
  METHODS
  Tissue samples from the primary lesion of GC in patients who accepted D2/D3 radical gastrectomy with R0/R1 resection were stained by immunohistochemistry of c-MET, p-MET, e2f-1 and Ki-67. The univariate and the multivariate analyses involving in clinicopathological parameters and prognostic factors were evaluated.
  
  
  RESULTS
  The positivity rates for c-MET (66.12%, 80 cases/121 cases), p-MET (59.50%, 72 cases/121 cases), e2f-1 (38.84%, 47 cases/121 cases) and Ki-67 (72.73%, 88 cases/121 cases) in primary lesion of GC was significantly higher than that in non-cancerous tissue at 5 cm places far from the margin of primary lesion (P < 0.05, respectively). The deeper tumor invasion, the severer lymph node metastasis, the later stage of TNM and the higher expression of Ki-67 was respectively an independent risk factor for the higher expression of c-MET or p-MET, but the younger age and the shorter survival time was an independent risk factor for the higher expression of e2f-1 respectively. Survival analysis showed that the worse prognosis could be observed in the patients with the combination of both c-MET-positive and e2f-1-negative (P = 0.038) or both p-MET-positive and e2f-1-negative (P = 0.042). Cox analysis demonstrated that the severer lymphatic node metastasis and the higher positivity rate of c-MET, p-MET or e2f-1 were an independent prognosis factor respectively. The higher expression of e2f-1 was identified in patients with Stage I-II, which correlated with a shorter survival time. Survival analysis also revealed that the prognosis of patients with positive expression of e2f-1 at Stage I-II was significantly worse than that in patients with negative expression of e2f-1 (χ2 = 13.437, P = 0.001). However, in the cases with Stage III-IV, no significant difference could be identified in the prognostic comparison between positive and negative expressions of e2f-1.
  
  
  CONCLUSIONS
  The expression of c-MET or p-MET is an independent prognosis factor. It has been observed that the higher expression of e2f-1 occurred in the early stages while the lower expression of it in the later stages in GC.
authors.forename: Ju-gang
authors.initials: JG
authors.lastname: Wu
authors.forename: Ji-wei
authors.initials: JW
authors.lastname: Yu
authors.forename: Hong-biao
authors.initials: HB
authors.lastname: Wu
authors.forename: Lin-hai
authors.initials: LH
authors.lastname: Zheng
authors.forename: Xiao-chun
authors.initials: XC
authors.lastname: Ni
authors.forename: Xiao-qiang
authors.initials: XQ
authors.lastname: Li
authors.forename: Guang-ye
authors.initials: GY
authors.lastname: Du
authors.affiliation: 1st Department of General Surgery, Shanghai 3rd People's Hospital, School of Medicine, Shanghai Jiao Tong University, No, 280, Mohe Road, Shanghai 201900, China. Jiang-bj2102@hotmail.com.
authors.forename: Bo-jian
authors.initials: BJ
authors.lastname: Jiang
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000235:genetics / Q000473:pathology / Q000556:secondary; D000368:Aged; D050687:E2F1 Transcription Factor / Q000032:analysis* / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D009367:Neoplasm Staging; D010766:Phosphorylation; D011379:Prognosis; D016016:Proportional Hazards Models; D011499:Protein Processing, Post-Translational; D019859:Proto-Oncogene Proteins c-met / Q000032:analysis* / Q000235:genetics / Q000378:metabolism; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology
chemical_list: D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D019859:Proto-Oncogene Proteins c-met